Methoxsalen
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Methoxsalen
- Methoxsalen: From Cutaneous T-Cell Lymphoma Photopheresis to Localized Pagetoid Reticulosis
Methoxsalen: From Cutaneous T-Cell Lymphoma Photopheresis to Localized Pagetoid Reticulosis
One-Sentence Summary
Methoxsalen is a psoralen photosensitizer whose established clinical use (via extracorporeal photopheresis, ECP/UVADEX) targets circulating malignant T-cells in cutaneous T-cell lymphoma (CTCL). The TxGNN model’s top-ranked prediction is Localized Pagetoid Reticulosis, a rare, localized CTCL subtype, but this specific prediction currently has no registered clinical trials and no supporting literature — it rests on class-effect extrapolation from methoxsalen’s known CTCL biology rather than direct evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in this evidence pack — methoxsalen is not currently marketed in Taiwan and no approved-indication record exists. (Contextual note: evidence embedded in the pack describes methoxsalen/8-MOP as the basis of extracorporeal photopheresis, an established CTCL treatment.) |
| Predicted New Indication | Localized Pagetoid Reticulosis |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L4 |
| Market Status (Taiwan) | 未上市 (Not Marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for methoxsalen is not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on information embedded elsewhere in the pack, methoxsalen (8-MOP) is a furocoumarin (psoralen) photosensitizer: once activated by UVA light, it forms covalent crosslinks with DNA pyrimidine bases, halting proliferation of the exposed cells. This photoactivated DNA-crosslinking mechanism is the pharmacological basis of extracorporeal photopheresis (ECP), an established treatment for the circulating malignant T-cells of cutaneous T-cell lymphoma.
Localized Pagetoid Reticulosis is a rare, indolent, localized subtype within the mycosis fungoides/CTCL disease spectrum — the same disease family that ECP already addresses. This gives the prediction mechanistic plausibility: the anti-proliferative, DNA-damaging photochemotherapy effect that clears malignant T-cells elsewhere in CTCL could plausibly extend to this localized variant.
However, this rationale is a class-effect extrapolation, not direct evidence — no trials or publications specific to this subtype exist yet. For context, a related and broader prediction in the same evidence pack, “indolent primary cutaneous T-cell lymphoma” (rank 2), is supported by 2 literature citations and carries a stronger evidence rating (L2, “Proceed with Guardrails”), reinforcing that methoxsalen’s CTCL-photopheresis mechanism is real and applicable — just not yet demonstrated for this particular localized subtype.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
US Market Information
No Taiwan market authorization records are available — methoxsalen is not currently marketed in Taiwan (0 licenses on file), so no NDA/product table can be generated.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Although methoxsalen’s DNA-crosslinking, photoactivated mechanism gives this prediction biological plausibility, Localized Pagetoid Reticulosis has zero direct trials or literature — evidence level L4 reflects mechanistic reasoning only, not demonstrated efficacy in this specific indication.
To proceed, the following is needed:
- TFDA package insert warnings/contraindications (Blocking data gap — required before any S1 safety screening can proceed)
- Full mechanism of action documentation for methoxsalen (DrugBank API lookup)
- Dedicated case series or pilot data specific to localized pagetoid reticulosis, rather than class-effect extrapolation from broader CTCL/ECP use
- Confirmation of a Taiwan registration pathway, since the drug is not currently marketed (0 licenses)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.